De­tails emerge on Cidara/J&J in­fluen­za part­ner­ship, with a count­down on next steps

Cidara has fi­nal­ly giv­en more de­tails on its in­fluen­za deal with John­son and John­son’s Janssen af­ter the part­nered can­di­date was re­moved from the phar­ma gi­ant’s pipeline last month.

Some de­tails have come out since late Ju­ly. But San Diego-based Cidara, in its sec­ond-quar­ter earn­ings an­nounce­ment Thurs­day, is now giv­ing a more com­plete pic­ture of its flu deal.

The com­pa­ny not­ed that its in­fluen­za can­di­date CD388 — al­so re­ferred to as JNJ-0953 — was no longer dis­played in Janssen’s pipeline as of Ju­ly 20. It’s a part of Janssen’s plans to dis­con­tin­ue in­ter­nal de­vel­op­ment of sev­er­al in­fec­tious dis­ease can­di­dates, in­clud­ing JNJ-0953.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER